Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme J. Moyle

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current HIV/AIDS Reports|August 11, 2005
Plastic surgical approaches for HIV-associated lipoatrophyGraeme J Moyle
Current Opinion in Infectious Diseases|April 20, 2002
Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infectionGraeme J. Moyle
The AIDS Reader|August 29, 2006
Bone mineral abnormalities in persons with HIV infection: signal or noise?Kasha Singh, Graeme J Moyle
Clinical Drug Investigation|February 22, 2014
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infectionGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
AIDS Reviews|February 11, 2005
Considerations in selecting protease inhibitor therapyBrian A Boyle, Richard A Elion, Graeme J Moyle, et al.
Antiviral Therapy|April 14, 2010
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteersPaul A Randell, Akil G Jackson, Lijie Zhong, et al.
AIDS (London, England)|July 20, 2002
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factorsGraeme J Moyle, Debasis Datta, Sundhiya Mandalia, et al.
Journal of Immune Based Therapies and Vaccines|November 4, 2008
Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-upAnna A Herasimtschuk, Samantha J Westrop, Graeme J Moyle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 9, 2014
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudyGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
AIDS Care|April 9, 2011
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenzVanessa Cooper, Graeme J Moyle, Martin Fisher, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current HIV/AIDS Reports|August 11, 2005
Plastic surgical approaches for HIV-associated lipoatrophyGraeme J Moyle
Current Opinion in Infectious Diseases|April 20, 2002
Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infectionGraeme J. Moyle
The AIDS Reader|August 29, 2006
Bone mineral abnormalities in persons with HIV infection: signal or noise?Kasha Singh, Graeme J Moyle
Clinical Drug Investigation|February 22, 2014
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infectionGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
AIDS Reviews|February 11, 2005
Considerations in selecting protease inhibitor therapyBrian A Boyle, Richard A Elion, Graeme J Moyle, et al.
Antiviral Therapy|April 14, 2010
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteersPaul A Randell, Akil G Jackson, Lijie Zhong, et al.
AIDS (London, England)|July 20, 2002
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factorsGraeme J Moyle, Debasis Datta, Sundhiya Mandalia, et al.
Journal of Immune Based Therapies and Vaccines|November 4, 2008
Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-upAnna A Herasimtschuk, Samantha J Westrop, Graeme J Moyle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 9, 2014
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudyGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
AIDS Care|April 9, 2011
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenzVanessa Cooper, Graeme J Moyle, Martin Fisher, et al.
Pageof 3